These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 34890875)

  • 41. In Silico Prediction of Diffusion Interaction Parameter (k
    Tomar DS; Singh SK; Li L; Broulidakis MP; Kumar S
    Pharm Res; 2018 Aug; 35(10):193. PubMed ID: 30128780
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Solution pH that minimizes self-association of three monoclonal antibodies is strongly dependent on ionic strength.
    Sule SV; Cheung JK; Antochshuk V; Bhalla AS; Narasimhan C; Blaisdell S; Shameem M; Tessier PM
    Mol Pharm; 2012 Apr; 9(4):744-51. PubMed ID: 22221144
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Therapeutic Monoclonal Antibodies to Complex Membrane Protein Targets: Antigen Generation and Antibody Discovery Strategies.
    Dodd RB; Wilkinson T; Schofield DJ
    BioDrugs; 2018 Aug; 32(4):339-355. PubMed ID: 29934752
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Application of a high-throughput screening procedure with PEG-induced precipitation to compare relative protein solubility during formulation development with IgG1 monoclonal antibodies.
    Gibson TJ; Mccarty K; Mcfadyen IJ; Cash E; Dalmonte P; Hinds KD; Dinerman AA; Alvarez JC; Volkin DB
    J Pharm Sci; 2011 Mar; 100(3):1009-21. PubMed ID: 21280052
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Early developability screen of therapeutic antibody candidates using Taylor dispersion analysis and UV area imaging detection.
    Lavoisier A; Schlaeppi JM
    MAbs; 2015; 7(1):77-83. PubMed ID: 25514497
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Application of a kosmotrope-based solubility assay to multiple protein therapeutic classes indicates broad use as a high-throughput screen for protein therapeutic aggregation propensity.
    Yamniuk AP; Ditto N; Patel M; Dai J; Sejwal P; Stetsko P; Doyle ML
    J Pharm Sci; 2013 Aug; 102(8):2424-39. PubMed ID: 23712759
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Biophysical properties of the clinical-stage antibody landscape.
    Jain T; Sun T; Durand S; Hall A; Houston NR; Nett JH; Sharkey B; Bobrowicz B; Caffry I; Yu Y; Cao Y; Lynaugh H; Brown M; Baruah H; Gray LT; Krauland EM; Xu Y; Vásquez M; Wittrup KD
    Proc Natl Acad Sci U S A; 2017 Jan; 114(5):944-949. PubMed ID: 28096333
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Estimation of the Viscosity of an Antibody Solution from the Diffusion Interaction Parameter.
    Shimomura T; Sekiguchi M; Honda R; Yamazaki M; Yokoyama M; Uchiyama S
    Biol Pharm Bull; 2022; 45(9):1300-1305. PubMed ID: 36047198
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Developability studies before initiation of process development: improving manufacturability of monoclonal antibodies.
    Yang X; Xu W; Dukleska S; Benchaar S; Mengisen S; Antochshuk V; Cheung J; Mann L; Babadjanova Z; Rowand J; Gunawan R; McCampbell A; Beaumont M; Meininger D; Richardson D; Ambrogelly A
    MAbs; 2013; 5(5):787-94. PubMed ID: 23883920
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Predictive Screening Tools Used in High-Concentration Protein Formulation Development.
    Hofmann M; Gieseler H
    J Pharm Sci; 2018 Mar; 107(3):772-777. PubMed ID: 29102552
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Phage Display Derived Monoclonal Antibodies: From Bench to Bedside.
    Alfaleh MA; Alsaab HO; Mahmoud AB; Alkayyal AA; Jones ML; Mahler SM; Hashem AM
    Front Immunol; 2020; 11():1986. PubMed ID: 32983137
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Ongoing Challenges to Develop High Concentration Monoclonal Antibody-based Formulations for Subcutaneous Administration: Quo Vadis?
    Jiskoot W; Hawe A; Menzen T; Volkin DB; Crommelin DJA
    J Pharm Sci; 2022 Apr; 111(4):861-867. PubMed ID: 34813800
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Solubility Challenges in High Concentration Monoclonal Antibody Formulations: Relationship with Amino Acid Sequence and Intermolecular Interactions.
    Pindrus M; Shire SJ; Kelley RF; Demeule B; Wong R; Xu Y; Yadav S
    Mol Pharm; 2015 Nov; 12(11):3896-907. PubMed ID: 26407030
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Characterization of Excipient Effects on Reversible Self-Association, Backbone Flexibility, and Solution Properties of an IgG1 Monoclonal Antibody at High Concentrations: Part 1.
    Hu Y; Arora J; Joshi SB; Esfandiary R; Middaugh CR; Weis DD; Volkin DB
    J Pharm Sci; 2020 Jan; 109(1):340-352. PubMed ID: 31201906
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Unique Impacts of Methionine Oxidation, Tryptophan Oxidation, and Asparagine Deamidation on Antibody Stability and Aggregation.
    Alam ME; Slaney TR; Wu L; Das TK; Kar S; Barnett GV; Leone A; Tessier PM
    J Pharm Sci; 2020 Jan; 109(1):656-669. PubMed ID: 31678251
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Current advances in biopharmaceutical informatics: guidelines, impact and challenges in the computational developability assessment of antibody therapeutics.
    Khetan R; Curtis R; Deane CM; Hadsund JT; Kar U; Krawczyk K; Kuroda D; Robinson SA; Sormanni P; Tsumoto K; Warwicker J; Martin ACR
    MAbs; 2022; 14(1):2020082. PubMed ID: 35104168
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Membrane protein production and formulation for drug discovery.
    Gulezian E; Crivello C; Bednenko J; Zafra C; Zhang Y; Colussi P; Hussain S
    Trends Pharmacol Sci; 2021 Aug; 42(8):657-674. PubMed ID: 34270922
    [TBL] [Abstract][Full Text] [Related]  

  • 58. In silico selection of therapeutic antibodies for development: viscosity, clearance, and chemical stability.
    Sharma VK; Patapoff TW; Kabakoff B; Pai S; Hilario E; Zhang B; Li C; Borisov O; Kelley RF; Chorny I; Zhou JZ; Dill KA; Swartz TE
    Proc Natl Acad Sci U S A; 2014 Dec; 111(52):18601-6. PubMed ID: 25512516
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Generating therapeutic monoclonal antibodies to complex multi-spanning membrane targets: Overcoming the antigen challenge and enabling discovery strategies.
    Dodd R; Schofield DJ; Wilkinson T; Britton ZT
    Methods; 2020 Aug; 180():111-126. PubMed ID: 32422249
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Therapeutic Antibody Engineering To Improve Viscosity and Phase Separation Guided by Crystal Structure.
    Chow CK; Allan BW; Chai Q; Atwell S; Lu J
    Mol Pharm; 2016 Mar; 13(3):915-23. PubMed ID: 26849155
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.